Clinical Trial Update: Effect of Henagliflozin on Myocardial Fibrosis in Non-Obstructive HCM: A Randomized, Double-Blind, Placebo-Controlled Trial Using 68Ga/18F-FAPI PET/CMR [NA]

View source ↗

Summary

A randomized, double-blind, placebo-controlled trial of Henagliflozin for myocardial fibrosis in non-obstructive hypertrophic cardiomyopathy; currently not recr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertrophic Cardiomyopathy

Drugs mentioned

• Henagliflozin (henagliflozin)

Snippet

Sponsor: Shanghai East Hospital | Conditions: HCM - Hypertrophic Cardiomyopathy | NA | Status: NOT_YET_RECRUITING